Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6971232 | 0.83 | AKT1 (0.39) | SQORKMT2AMAPTALDH1A1CYP1A2 | |
| SCHEMBL3263121 | 0.79 | MAPK1 (0.43) | SQORSMN1; SMN2NPC1NFKB1RAB9A | |
| SCHEMBL218119 | 0.79 | ALOX15 (0.52) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL25274257 | 0.77 | METAP2 (0.43) | SQORMAPTALDH1A1METAP2AKT1 | |
| SCHEMBL10432295 | 0.76 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL1386288 | 0.76 | NPC1 (0.35) | SQORNPC1RAB9AKMT2AMAPT | |
| SCHEMBL3379956 | 0.75 | AKT2 (0.44) | SQORKMT2AALDH1A1METAP2AKT1 | |
| SCHEMBL28197453 | 0.75 | ALOX15 (0.43) | RAB9AMAPTALDH1A1AKT1AKT2 | |
| SCHEMBL1386673 | 0.74 | SQOR (0.49) | SQORNFKB1MAPTALDH1A1CYP1A2 | |
| SCHEMBL25276134 | 0.74 | KDM4E (0.44) | SQORSMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833078-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2009-07-02 | — | — | US | claimed |
| EP-1689720-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | Aventis Pharma S.A. (FR) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | claimed |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | claimed |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| CN-119031913-A | Purine and methods of use thereof | 奇尼塔公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444312-A2 | PURINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444316-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-1171484-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1169360-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| EP-1159316-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000058373-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000058372-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000058371-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000052069-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | SQOR 4345/4885SMN1; SMN2 495/4885NPC1 677/4885 |
| US-20090170833-A1 | PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | C1R, CBR3, C3AR1 | SQOR 2350/4885SMN1; SMN2 2169/4885NPC1 2266/4885 |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | SQOR 279/4885SMN1; SMN2 7/4885NPC1 1817/4885 |
| US-20050165005-A1 | Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them | C1R, CBR3, C3AR1 | SQOR 2334/4885SMN1; SMN2 2172/4885NPC1 2165/4885 |
| US-20250353851-A1 | PURINES AND METHODS OF THEIR USE | TDP1, TDP2, PIKFYVE | SQOR 4265/4885SMN1; SMN2 77/4885NPC1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.